Asston Pharmaceuticals IPO is a book-built issue IPO, aiming to raise ₹80.08 crore. It comprises of a a fresh issue of 26.00 lakh equity shares aggregating to ₹64.48 crore and an offer for sale of 6.29 lakh equity shares worth ₹15.60 crore. The bidding window was open from July 7, 2025, to July 9, 2025, with the IPO allotment to be finalised on July 10, 2025. Asston Pharmaceuticals is scheduled to list on BSE SME on July 14, 2025.
The IPO was priced at a range of ₹236-₹248 per share with a lot size of 600 shares. The public issue received bids for 1,27,18,200 shares against 21,51,600 shares available, resulting in an overall subscription of 5.91 times. QIBs led the response, subscribing 13.69 times their quota, followed by retail investors at 5.64 times.
· Go to the application status page.
· Select "Equity and SME IPO bids".
· Choose "Asston Pharmaceuticals" from the Issue Name dropdown.
· Provide your Application Number or PAN.
· Click on Submit.
· Go to the application status page.
· Select "Equity" under the Issue Type.
· Choose "Asston Pharmaceuticals" from the Issue Name dropdown.
· Provide your Application Number or PAN.
· Click on “I am not a robot” and submit.
· Go to the registrar’s official website.
· Select "Asston Pharmaceuticals" from the company list.
· Enter your Client ID, Application Number, or PAN.
· Click on Submit.
Asston Pharmaceuticals' ₹80.08 crore IPO, priced at a range of ₹236-₹248 per share, was subscribed 5.91 times overall. The IPO is a fresh issue of 26.00 lakh equity shares aggregating to ₹64.48 crore and an offer for sale of 6.29 lakh equity shares worth ₹15.60 crore. Bidding took place from July 7 to July 9, 2025, with the Asston Pharmaceuticals IPO allotment status on July 10, 2025. Retail investors subscribed 1.63 and NIIs 5.64 times. Listing is expected on July 14, 2025.
The table below breaks down the Asston Pharmaceuticals share allocation for different categories, highlighting the number of shares and their percentage of the total issue. However, the key focus remains on the quotas allocated to retail investors and HNIs, as they are the most relevant for individual investors.
Investor Category | Shares Offered |
Market Maker Shares Offered | 1,66,200 (5.15%) |
QIB Shares Offered | 15,21,000 (47.10%) |
− Anchor Investor Shares Offered | 9,11,400 (28.22%) |
− QIB (Ex. Anchor) Shares Offered | 6,09,600 (18.88%) |
NII (HNI) Shares Offered | 4,63,200 (14.34%) |
Retail Shares Offered | 10,78,800 (33.41%) |
Total Shares Offered | 32,29,200 (100.00%) |
Data Source: BSE
Category | Subscription (times) |
Qualified Institutional Buyers | 13.69 |
Non-Institutional Investors | 5.64 |
Retail Individual Investors | 1.63 |
Total shares | 5.91 |
Note: The subscription details are as of July 9, 2025
Asston Pharmaceuticals Limited was originally incorporated as Asston Pharmaceuticals Private Limited on 6 March 2020 under the Companies Act, 2013. The company was subsequently converted into a public limited entity and renamed Asston Pharmaceuticals Limited on 4 October 2024, following resolutions passed by its Board and shareholders.
Headquartered in Mumbai, Maharashtra, Chemkart is engaged in the processing and trading of nutritional and health supplements. The company operates primarily in the B2B segment, supplying raw materials used in the manufacture of finished products such as sports supplements, vitamins, proteins, and herbal extracts. Its product portfolio spans seven key categories: amino acids, health supplements, herbal extracts, nucleotides, proteins, sports nutrition, and vitamins.
Chemkart maintains a warehouse and processing facility in Bhiwandi, Thane, covering approximately 28,259 square feet. This facility is equipped with blending and grinding machinery capable of processing up to 990 metric tonnes annually, enabling the company to offer customised formulations tailored to client specifications.
In September 2024, Chemkart acquired 99% stakes in Easy Raw Materials Private Limited and Vinstar Biotech Private Limited, marking its strategic entry into backward integration. Through its wholly owned subsidiary ERMPL, the company plans to establish a manufacturing unit within the Jawaharlal Nehru Port Authority (JNPA) Special Economic Zone, further enhancing its production capabilities and export potential.
Know more about IPO allotment status and check your application details online for the latest updates on share allocation.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Jul 11, 2025, 9:10 PM IST
Akshay Shivalkar
Akshay Shivalkar is a financial content specialist who strategises and creates SEO-optimised content on the stock market, mutual funds, and other investment products. With experience in fintech and asset management, he simplifies complex financial concepts to help investors make informed decisions through his writing.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
